Highest-materiality recent filing
Tilray Q1 FY27 revenue up 23% to $257.1M; net loss $40M on non-cash charges, BrewDog lifts beverage
Net revenue $257.1M, up 23% YoY from $209.5M; gross profit $77.5M (+35%) with gross margin expanding ~300 bps to 30%.
Tilray exchanges 2.84M shares for $12M of 5.20% convertible notes
Issued 2,841,650 common shares to retire $12M principal of 5.20% Convertible Senior Notes due 2027.
Tilray issues 1.38M shares to retire $6M of 5.20% convertible notes
Exchanged 1,377,334 common shares for $6M aggregate principal of 5.20% Convertible Senior Notes due June 15, 2027.
FY2026 net revenue $915.5M (+11% YoY); adjusted EBITDA $61.1M; net loss $105.2M ($1.09 loss per share).
Tilray exchanges $12M of 5.20% convertible notes for 2.64M common shares
Issued 2,638,341 common shares in exchange for $12M aggregate principal of 5.20% Convertible Senior Notes due June 15, 2027.
Tilray issues 1.2M shares to convert $6M debt, plus 398k shares for Lyphe deal
Issued 398,666 shares as partial consideration for the Lyphe Group acquisition.
Tilray Brands files routine legal exhibit; no material change to operations
Filing relates to Registration Statement No. 333-290806.
Tilray issues 1.88M shares to exchange $12M in convertible notes due 2027
Issued 1,879,696 common shares in private debt-for-equity exchange for $12M principal of 5.20% Convertible Senior Notes due June 15, 2027.
Tilray acquires UK medical platform Lyphe; files $180M ATM for beverage expansion
Acquired Lyphe Group, a UK medical cannabis clinic/pharmacy; dispensed ~150K units, treated 16K+ patients; expected accretive in 2027.
Tilray Brands Q3 FY2026 revenue $207M record; intl cannabis +73%; buys BrewDog ~£40M
Record Q3 net revenue of $207M, up 11% organic YoY; gross profit $55M, up 6% YoY.
Tilray Brands acquires BrewDog assets for £33M; eyes $200M annual revenue from acquisition
Acquired BrewDog's global IP, UK brewing ops, and 11 brewpubs for £33M (~$44.1M) via pre-pack administration.
Tilray Brands Q2 FY2026 revenue record $218M; net cash $30M; reaffirms EBITDA guidance
Net revenue $218M, a record quarterly; international medical cannabis revenue increased 36% YoY.
Tilray announces 1-for-10 reverse stock split effective Dec 1, 2025
Reverse stock split ratio one-for-ten; shares outstanding reduce from 1.16B to ~116M.
Tilray shareholders reject board declassification; say-on-pay passes with ~70%
Re-elected John Herhalt as Class I director: 85.5M for, 23.4M against, 326.9M broker non-votes.
Tilray files 8-K with investor presentation; no specific new facts in filing text
Investor presentation dated Nov 17, 2025 made available on Tilray's IR website.
Tilray Brands Q1 FY2026 net revenue $210M, net income $1.5M, EBITDA +9%
Net revenue $209.5M (+5% YoY); net income $1.5M vs net loss $34.7M prior year.
Tilray files legal opinion for Registration Statement; no material news
Filed opinion of DLA Piper LLP (US) in connection with Registration Statement No. 333-267788.
Tilray Q4/FY2025: net loss $1.27B on $2.1B impairment; guides FY2026 EBITDA $62-72M
FY2025 net revenue $821.3M (+4% YoY); Q4 net revenue $224.5M (down 2% from $229.9M).
Tilray issues 12.6M shares in exchange for $5M of 5.20% Convertible Notes due 2027
Issued 12,591,816 common shares to retire $5M principal of 5.20% Convertible Senior Notes due June 1, 2027.
Tilray shareholders approve reverse stock split up to 1-for-20
Shareholders approved amendment to allow reverse stock split at ratio between 1:10 and 1:20; 251M for, 182M against.
Tilray exchanges $9.4M convertible notes for 19M shares in private deals
Issued 19,034,603 common shares in exchange for $9.4M aggregate principal of 5.20% Convertible Senior Notes due June 2027.
Tilray proposes reverse stock split (1:10 to 1:20) at special meeting June 10, 2025
Special meeting of stockholders set for June 10, 2025 to vote on reverse stock split.
Tilray Q3 net revenue $186M; adjusted EBITDA $9M; cannabis margin up 800bps; debt reduced $71M
Net revenue $185.8M vs $188.3M prior year; constant currency ~$193M; SKU rationalization hit $13.2M.
Tilray Brands gets 180 days to cure Nasdaq minimum bid price deficiency
Received Nasdaq notice on March 25, 2025 for non-compliance with $1.00 minimum bid price rule.
Tilray to issue up to 23M shares in exchange for $14.6M convertible notes
Up to 23M shares issued in private exchange for $14.6M principal of 5.20% Convertible Notes due June 2027.
Tilray subsidiary refinances CAD $53M term loan to CIBC; extends maturity to 2028
Aphria Diamond Inc. entered a CAD $53M credit agreement with CIBC on Feb 21, 2025.
Tilray subsidiary Aphria settles Canadian class action for CAD 30M; no admission of liability
Settled for CAD 30M (US 21M), far below original CAD 875M claim; dismissal with prejudice.
Tilray to issue up to 21M shares in exchange for $22M in convertible notes
Issues up to 21M common shares for $22M aggregate principal of 5.20% Convertible Senior Notes due 2027.
Tilray Brands Q2 revenue up 9% to $211M; gross profit +29%; reaffirms FY2025 guidance
Net revenue $211M (record Q2), +9% YoY; gross margin 29% vs 24% prior year.
Tilray shareholders approve increase in authorized common shares to 1.426B from 1.208B
Shareholders voted 223.3M For, 153.5M Against, 6.5M Abstain on increasing authorized common stock.
Tilray Brands appoints Steven M. Cohen as Class III director
Appointed effective Dec. 8, 2024, as Class III director with term expiring at 2027 annual meeting.
Delaware court grants summary judgment for Tilray in proxy vote lawsuit
Court held Tilray correctly used majority-of-votes-cast standard for authorized share proposals; granted summary judgment for Tilray and directors.
Tilray annual meeting: authorized shares proposal adjourned, governance changes rejected
David Hopkinson and Thomas Looney elected as Class III directors; Jodi Butts term ended.
Tilray faces shareholder class action challenging authorized share vote standard
Lawsuit filed Oct 31, 2024 in Delaware Chancery claims proxy statements improperly used votes-cast standard instead of majority-of-outstanding shares for share increases.
Tilray amends credit facility to consent to Molson Coors craft beer acquisition
Fourth Amendment consents to Mack Acquisition of six craft beer brands from Molson Coors.
Tilray Q1 revenue $200M (+13%), net loss narrows; beverage alcohol up 132%
Net revenue $200M (+13% YoY); gross margin 30% (+500 bps) to $59.7M.
Tilray acquires $23.8M promissory note from DDH; issues 13.2M shares as consideration
Acquired $23.8M promissory note from Double Diamond Holdings (DDH) payable by Aphria Diamond.
Tilray FY2024 revenue up 26% to $789M, debt cut $291M, adjusted EBITDA $60.5M
Net revenue $788.9M (+26% YoY); Q4 revenue $229.9M (+25%).
May offer and sell up to $250M of common stock through TD Securities and Jefferies in at-the-market offerings.
Tilray converts $19.8M of 2024 convertible notes to 13.1M shares; only $330K notes remaining
Expects to issue up to 13.1M shares of common stock in exchange for $19.8M aggregate principal of 5.25% Convertible Senior Notes due June 1, 2024.
Tilray exchanges $19.8M of 5.25% convertible notes for 13.1M shares
Issued up to 13.1M shares of common stock to an unrelated party in exchange for $19.8M aggregate principal of 5.25% Convertible Senior Notes due June 2024.
Tilray to issue up to 15.2M shares in exchange for $24M of convertible notes
Between April 24 and May 6, 2024, Tilray entered private debt-for-equity exchanges with unrelated parties.
Tilray acquires $10.9M promissory note from JV partner, pays 6.1M shares
Tilray acquired a $10,883,496 promissory note payable by Aphria Diamond from Double Diamond Holdings.
Tilray Q3 revenue up 30% to $188M; adjusts FY EBITDA guidance to $60-63M
Net revenue $188.3M (+30% YoY); beverage-alcohol revenue surged 165% to $54.7M on craft acquisitions.
Tilray files routine legal opinion; no operational or financial news disclosed
Filing provides no new information on earnings, M&A, or business operations.
Tilray converts $12.54M of convertible notes into 6.87M shares
Issued 6,873,001 common shares in exchange for $12,540,000 principal of 5.25% Convertible Senior Notes due June 2024.
Tilray acquires $26.1M promissory note from joint venture partner, issues 12.4M shares
Entered assignment and assumption agreement with Double Diamond Holdings (DDH) to acquire a $26,134,500 promissory note.
Tilray Q2 FY2024 net revenue $194M (+34% YoY); net loss narrows to $46M
Record Q2 net revenue $194M vs $144M prior year; cannabis revenue up 35%, beverage alcohol up 117%.
Tilray exchanges $18.5M of convertible notes for 9.6M shares in private transactions
Issued 9,601,538 common shares to retire $18.5M aggregate principal of 5.25% Convertible Senior Notes due June 2024.
Tilray shareholders reject board declassification; approve share increase and auditor
Proposal to declassify board and eliminate for-cause removal failed with 78M for, 16M against.
Each of Michael Auerbach, Rebekah Dopp, Soren Schroder and Christine St.Clare (the “ Resigning Directors ”) resigned from the Board and from all committees of the Board of which such individual was a member, effective as of the Effective Time.
John M. Herhalt *(4) 63 Director
David F. Clanachan †(1) 59 Director
Renah Persofsky †(6)(7) 62 Director
Walter Robb *(1)(5) 66 Director
David Hopkinson ±(2)(3) 49 Director
Jodi Butts ±(3) 48 Director
Each of Michael Auerbach, Rebekah Dopp, Soren Schroder and Christine St.Clare (the “ Resigning Directors ”) resigned from the Board and from all committees of the Board of which such individual was a member, effective as of the Effective Time.
Thomas (Tom) Looney ± (1)(2) 57 Director
Brendan Kennedy, Tilray’s former chief executive officer and chairperson of the Board, submitted an irrevocable letter of resignation and release (the “ Letter of Resignation ”) whereby Mr. Kennedy resigned from all positions held at Tilray (other than as a member of the Board)
Irwin D. Simon † 62 Chairperson of the Board of Directors
Each of Michael Auerbach, Rebekah Dopp, Soren Schroder and Christine St.Clare (the “ Resigning Directors ”) resigned from the Board and from all committees of the Board of which such individual was a member, effective as of the Effective Time.
Max materiality 0.85 · Median 0.60 · Most common event other_material